Iranian Journal of Otorhinolaryngology (Mar 2024)

Effect of Combination Montelukast and Nasal Mometasone on Childhood Adenoid Hypertrophy

  • Mohsen Jafari,
  • Bahar Pourroshani,
  • Kambiz Eftekhari,
  • Armen Malekiantaghi,
  • Parisa Ashournia,
  • Alireza Shafiei

DOI
https://doi.org/10.22038/ijorl.2024.73906.3490
Journal volume & issue
Vol. 36, no. 2
pp. 391 – 397

Abstract

Read online

Introduction: Adenoid hypertrophy is a common childhood disease; its standard treatment is adenoidectomy. The desire for medical management is increasing due to fewer complications and more convenience. The present study investigated the effect of adding oral montelukast to mometasone nasal spray in treating adenoid hypertrophy. Materials and Methods: This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention. Results: Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576). Conclusion: The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.

Keywords